Accession Number: | 0001209191-23-020848 |
Date: | 2023-03-21 |
Issuer: | TYRA BIOSCIENCES, INC. (TYRA) |
Original Submission Date: |
HARRIS TODD
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET
CARLSBAD, CA 92008
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-03-21 | M | 12,393 | a | $2.25 | 1,713,669 | direct | ||
COMMON STOCK | 2023-03-21 | S | 12,393 | d | $16.00 | 1,701,276 | direct | ||
COMMON STOCK | 2023-03-22 | M | 4,043 | a | $2.25 | 1,705,319 | direct | ||
COMMON STOCK | 2023-03-22 | S | 4,043 | d | $16.00 | 1,701,276 | direct | ||
COMMON STOCK | 2023-03-23 | M | 2,800 | a | $2.25 | 1,704,076 | direct | ||
COMMON STOCK | 2023-03-23 | S | 2,800 | d | $16.00 | 1,701,276 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 2.25 | 2023-03-21 | deemed execution date | M | 12,393 (d) | 2031-03-09 | common stock 12,393 | $2.25 | 416,619 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.25 | 2023-03-22 | deemed execution date | M | 4,043 (d) | 2031-03-09 | common stock 4,043 | $2.25 | 412,576 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.25 | 2023-03-23 | deemed execution date | M | 2,800 (d) | 2031-03-09 | common stock 2,800 | $2.25 | 409,776 | direct |
ID | footnote |
---|---|
f1 | the sales reported on this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person in march 2022. |
f2 | 1/48th of the shares subject to the option vest monthly following march 5, 2021, the vesting commencement date. |